Merck & Co and Sanofi-Aventis ditch animal health agreement
This article was originally published in Scrip
Merck & Co and Sanofi-Aventis have announced they will be abandoning their agreement to form a new animal health joint venture by merging their animal health businesses. In March 2010, the firms announced the deal that would see Merck and Sanofi-Aventis combine their two animal health assets and businesses, Intervet/Schering-Plough and Merial, respectively.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.